

# MagArray REVEAL

## LUNG NODULE CHARACTERIZATION

### FINAL REPORT

Collected: DDMMYYYY

Received: DDMMYYYY


Report Date: DDMMYYYY

Referring Physician: XXXXXXXXXXXXXXXX  
 Physician NPI#: XXXXXXXXXXXXXXXX  
 Address: XXXXXXXXXXXXXXXX  
 City / State / Zip: XXXXXXXXXXXXXXXX  
 Fax Number: XXXXXXXXXXXXXXXX

Specimen Number: XXXXXXXXXXXXXXXX  
 Patient Name: XXXXXXXXXXXXXXXX  
 DOB: XXXXXXXXXXXXXXXX

### REVEAL Lung Nodule Characterization Test Results

#### RISK OF NODULE MALIGNANCY



Reportable Range	Patient REVEAL Result		
0-100	Specimen Number	Score	Risk Category
	XXXXXXXXXXXX	XX	<b>Lower</b>

### Lower Risk

A relatively lower risk of lung cancer, which is consistent with REVEAL scores in a clinical study where 94% of the subjects with a score of 49 or less had benign disease<sup>1</sup>. REVEAL is a risk assessment tool, which is to be used in conjunction with standard clinical assessments. *The test is not intended as a screening or stand-alone diagnostic assay.*

<sup>1</sup> Trivedi et al., Biomedical Research and Clinical Practice, 2018

Indeterminate pulmonary nodules (IPN) detected by imaging pose a significant clinical challenge because the vast majority (96%) of IPN are benign. To reduce overdiagnosis and overtreatment of non-cancerous IPN found on chest imaging, an accurate, noninvasive and easily administered test is needed to better assess the risk of malignancy. The REVEAL blood test has demonstrated efficacy in accurately identifying patients at low risk of lung cancer to help rule-out the need for risky and costly aggressive actions<sup>1</sup>. The test has the potential to help support a more informed clinical decision about performing an invasive evaluation of the patient's lung nodule.

<sup>1</sup> Trivedi et al., Biomedical Research and Clinical Practice, 2018

This test was developed and the performance characteristics of this test were validated by MagArray, Inc. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. **The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.** MagArray, Inc. is licensed under Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity testing. Test performed at MagArray, Inc.

# MagArray REVEAL

## LUNG NODULE CHARACTERIZATION

### FINAL REPORT

Collected: DDMMYYYY

Received: DDMMYYYY


Report Date: DDMMYYYY

Referring Physician: XXXXXXXXXXXXXXXX  
 Physician NPI#: XXXXXXXXXXXXXXXX  
 Address: XXXXXXXXXXXXXXXX  
 City / State / Zip: XXXXXXXXXXXXXXXX  
 Fax Number: XXXXXXXXXXXXXXXX

Specimen Number: XXXXXXXXXXXXXXXX  
 Patient Name: XXXXXXXXXXXXXXXX  
 DOB: XXXXXXXXXXXXXXXX

### REVEAL Lung Nodule Characterization Test Results

#### RISK OF NODULE MALIGNANCY



Reportable Range	Patient REVEAL Result		
0-100	Specimen Number	Score	Risk Category
	XXXXXXXXXXXX	XX	<b>Higher</b>

### Higher Risk

A relatively higher risk of lung cancer, which is consistent with REVEAL scores in a clinical study where subjects with a score of 50 or higher had a relatively higher risk of having lung cancer<sup>1</sup>. REVEAL is a risk assessment tool, which is to be used only in conjunction with standard clinical assessments. *The test is not intended as a screening or stand-alone diagnostic assay.*

<sup>1</sup>Trivedi et al., Biomedical Research and Clinical Practice, 2018

Indeterminate pulmonary nodules (IPN) detected by imaging pose a significant clinical challenge because the vast majority (96%) of IPN are benign. To reduce overdiagnosis and overtreatment of non-cancerous IPN found on chest imaging, an accurate, noninvasive and easily administered test is needed to better assess the risk of malignancy. The REVEAL blood test has demonstrated efficacy in accurately identifying patients at low risk of lung cancer to help rule-out the need for risky and costly aggressive actions<sup>1</sup>. The test has the potential to help support a more informed clinical decision about performing an invasive evaluation of the patient's lung nodule.

<sup>1</sup> Trivedi et al., Biomedical Research and Clinical Practice, 2018

This test was developed and the performance characteristics of this test were validated by MagArray, Inc. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. **The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.**

MagArray, Inc. is licensed under Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity testing. Test performed at MagArray, Inc.